As CDK4-targeted therapy, CDK4/6 inhibitors (e.g., abemaciclib, palbociclib, ribociclib) are currently widely used for the treatment of breast cancer, and their therapeutic value in this disease context has attracted significant attention (30–33). Here, CDK4 is linked to breast carcinoma.